New hope for advanced stomach cancer patients who've run out of options
NCT ID NCT07364422
Summary
This study is testing whether a new drug called JPI-547, when combined with an existing chemotherapy drug (irinotecan), is safe and effective for people with advanced stomach cancer that has returned or spread. The trial is for patients who have already tried at least two other treatments without success. Researchers will first find the right dose, then see how well the combination shrinks tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER (GC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine
Seoul, South Korea
Contact
Conditions
Explore the condition pages connected to this study.